Blackstone Inc’s Arcutis Biotherapeutics ARQT Stock Holding History

Blackstone Inc’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-24,144	Closed	-$378K	–	174
2025 Q1	$378K	Hold	24,144	–	–	﹤0.01%	153
2024 Q4	$336K	Hold	24,144	–	–	﹤0.01%	151
2024 Q3	$225K	Hold	24,144	–	–	﹤0.01%	155
2024 Q2	$225K	Hold	24,144	–	–	﹤0.01%	167
2024 Q1	$239K	Hold	24,144	–	–	﹤0.01%	165
2023 Q4	$78K	Hold	24,144	–	–	﹤0.01%	157
2023 Q3	$128K	Hold	24,144	–	–	﹤0.01%	148
2023 Q2	$230K	Hold	24,144	–	–	﹤0.01%	146
2023 Q1	$266K	Hold	24,144	–	–	﹤0.01%	148
2022 Q4	$357K	Hold	24,144	–	–	﹤0.01%	142
2022 Q3	$461K	Hold	24,144	–	–	﹤0.01%	162
2022 Q2	$515K	Hold	24,144	–	–	﹤0.01%	176
2022 Q1	$465K	Hold	24,144	–	–	﹤0.01%	198
2021 Q4	$501K	Hold	24,144	–	–	﹤0.01%	347
2021 Q3	$577K	Buy	+24,144	New	+$551K	﹤0.01%	399

Other funds holding ARQT

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Blackstone Inc's ARQT Position: Q2 2025 in Review

Blackstone Inc sold out of Arcutis Biotherapeutics (ARQT) in Q2 2025, closing a stake of 24,144 shares — an estimated $378K sold.

Blackstone Inc first reported a position in ARQT in Q3 2021 and held it in 15 quarters. The position peaked at $577K in Q3 2021. 230 funds tracked by Wall St. Rank hold ARQT as of Q2 2025.

Blackstone Inc reported no remaining Arcutis Biotherapeutics position as of Q2 2025 after selling out during the quarter.
Blackstone Inc sold 24,144 Arcutis Biotherapeutics shares in Q2 2025, an estimated $378K.
Blackstone Inc first reported a position in Arcutis Biotherapeutics in Q3 2021 and held it in 15 quarters.
Blackstone Inc's Arcutis Biotherapeutics position peaked at $577K in Q3 2021.
230 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2025.

Based on Blackstone Inc's 13F filing for Q2 2025, filed 14 Aug 2025.